3rd China Vaccine Focus 2013
News Apr 10, 2013
“China lays out its 12th Five-Year Plan for biopharma industry and the gross output value may reach 3 trillion RMB by 2015 with growth rate of 20% per year. And much importance has been attached to vaccine, mAb, gene engineering and protein engineering, peptides, blood products.”
With the Strong Support from ABO, Bayhelix, KoreaBio, SBIA, and etc, we are targeting towards 300 delegates, 40 exhibitors, and 40 speakers at 3rd China Vaccine Focus 2013 By the present of senior officials from Ministry of Health, PRC, SFDA/ FDA, NICPBP to address the latest regulatory issues on development of China vaccine industry. Through two days’ various sessions such as keynote presentations, interactive panel discussions, case studies, cocktail party and scheduled one-to-one business meetings, you will hear the latest breaking perspectives of both Chinese and MNC vaccine leaders. They will provide insights into their own company strategies for the coming years and how each perceives the marketplace developments. It will help you to win the vaccine market competition and strengthen your company’s dynamic growth in China’s vaccine market.
With nearly 1.4 bn people and approximately 17 million newborns each year, China has already been the largest producer and user of world vaccine products. Enhancing disease prevention awareness in adults, the spread of influenza A/H1N1 and other infectious diseases and Chinese government’s increased investment in epidemic prevention systems, recent improvements in China’s regulation, market, and technology scenario are all together creating an optimistic outlook for its vaccine industry. It is predicted that the vaccine sales revenue of China will increase to 20 billion RMB by 2015 with the growth rate of 10.8%.
CDMC events are devoted to delivering business intelligence by creating opportunities for knowledge sharing and business networking. CDMC endeavors to be the premier platform for acquiring business opportunities and strive to be part of your decision making. We firmly position ourselves as a landmark provider of B to B media service featuring China concept and high acclamation of customer. We pride ourselves in growing with your business and China's economy.
Quotient Clinical Signs Cocrystal Agreement with NuformixNews
Partnership to evaluate cocrystal formulations using translational pharmaceutics.READ MORE